{"url_path":"/sec/cik-0001012477/8-k/2026-02-12/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-12","source_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","accession_number":"0001104659-26-013880","cik":"0001012477","ticker":null,"issuer_name":"AVADEL PHARMACEUTICALS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","primary_entity_key":"0001012477","primary_entity_name":"AVADEL PHARMACEUTICALS PLC"},"word_count":112,"has_tables":true,"body_markdown":"**Item 7.01****Regulation FD Disclosure.**\n\n \n\nOn February 12, 2026, the Company and Alkermes issued a joint\npress release announcing the successful completion of the Acquisition. A copy of the press release\nis furnished herewith as Exhibit 99.1 and incorporated by reference into this Item 7.01.\n\n \n\nThe information in this Item 7.01, and in Exhibit 99.1 furnished\nherewith, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities\nof that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except\nas shall be expressly set forth by specific reference in such a filing."}